Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells
- 4 March 2019
- journal article
- research article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (3) , 135
Abstract
Lung cancer patients develop acquired resistance to tyrosine kinase inhibitors including erlotinib (ERL) after few months of primary treatment. Evidently, new chemotherapy strategies to delay or...Keywords
This publication has 29 references indexed in Scilit:
- Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailabilityCarbohydrate Polymers, 2016
- Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the LungThe Oncologist, 2016
- Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction MechanismsMolecular Pharmaceutics, 2016
- Haste Makes Waste: The Interplay Between Dissolution and Precipitation of Supersaturating FormulationsThe AAPS Journal, 2015
- Development of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of ErlotinibAAPS PharmSciTech, 2015
- Development of Solid SEDDS, IV: Effect of Adsorbed Lipid and Surfactant on Tableting Properties and Surface Structures of Different SilicatesPharmaceutical Research, 2013
- Design and evaluation of Lumefantrine – Oleic acid self nanoemulsifying ionic complex for enhanced dissolutionDARU Journal of Pharmaceutical Sciences, 2013
- VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating SurvivinMolecular and Cellular Biochemistry, 2011
- Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapyInternational Journal of Cancer, 2010
- Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability?Journal of Pharmaceutical Sciences, 2009